BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.